BEAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Beam Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$24.19+0.72 (+3.07%)
Close on Oct 19, 2026
- Market cap
- $2.52B
- P/E (TTM)
- –
- Dividend yield
- –
Beam Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Beam Therapeutics | Industry median |
|---|---|---|
| Market Cap | $2.50B | $164.85M |
| Enterprise Value | $1.40B | $87.06M |
| PS Ratio | 16.01 | 3.60 |
| PB Ratio | 2.34 | 2.03 |
| P/TBV Ratio | 2.34 | 2.31 |
Enterprise value
| Measure | Beam Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 8.96 | 2.43 |
Income (trailing twelve months)
| Measure | Beam Therapeutics | Industry median |
|---|---|---|
| Revenue | $156.04M | $57.94M |
| Operating Income | -$378.02M | -$21.44M |
| Net Income | -$85.43M | -$22.46M |
| EBITDA | -$355.78M | -$16.91M |
| EPS (Diluted) | -$0.82 | -$0.83 |
Margins
| Measure | Beam Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -242.3% | -44.5% |
| Profit Margin | -54.7% | -39.2% |
| EBITDA Margin | -228.0% | -31.3% |
| FCF Margin | -238.9% | -8.85% |
Returns
| Measure | Beam Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -8.06% | -53.1% |
| Return on Assets (ROA) | -6.15% | -41.0% |
| Return on Capital Employed (ROCE) | -29.0% | -37.8% |
Growth
| Measure | Beam Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 158.9% | 6.01% |
| Revenue Growth (3Y CAGR) | 31.9% | 2.25% |
| Revenue Growth (5Y CAGR) | 466.3% | 6.42% |
Balance sheet
| Measure | Beam Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $1.20B | $62.42M |
| Total Debt | $100.26M | $120.13M |
| Net Cash (Debt) | $1.10B | $15.68M |
| Net Cash Per Share | $10.65 | $0.66 |
| Equity (Book Value) | $1.07B | $48.79M |
| Book Value Per Share | $10.33 | $1.36 |
| Tangible Book Value | $1.07B | $23.06M |
| Working Capital | $1.10B | $75.77M |
Financial position
| Measure | Beam Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 14.57 | 3.30 |
| Quick Ratio | 14.84 | 2.39 |
| Debt / Equity | 0.09 | 0.51 |
Cash flow (trailing twelve months)
| Measure | Beam Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$359.38M | -$12.35M |
| Capital Expenditures | -$13.39M | -$1.06M |
| Free Cash Flow | -$372.77M | -$20.28M |
| FCF Per Share | -$3.61 | -$0.42 |
Efficiency
| Measure | Beam Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.11 | 0.38 |
| Revenue Per Employee | $305.35K | $398.96K |
| Profits Per Employee | -$167.18K | -$703.34K |
| Employee Count | 511 | 74 |
Dividends and yields
| Measure | Beam Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -3.42% | -22.7% |
| FCF Yield | -14.9% | -9.07% |
Shares
| Measure | Beam Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 103,288,000 | 58,179,650 |
| Shares Change (YoY) | 16.3% | 11.1% |
| Shares Change (QoQ) | 0.51% | 0.54% |
| Float | 99,818,100 | 49,173,100 |
| Shares Held by Insiders | 3.36% | 11.6% |
| Shares Held by Institutions | 105.9% | 59.4% |
Taxes
| Measure | Beam Therapeutics | Industry median |
|---|---|---|
| Income Tax | $0 | $91.50K |
Scores
| Measure | Beam Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 2.99 | -0.24 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Beam Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.